Home Antibody All anti-KCNK2 antibodies
Write Review & Get Rewarded
Write a review and get rewarded!
Review this antibody and earn an OriGene coupon or Amazon giftcard
Follow these easy steps to reward yourself:
- Sign in to your account, or register for a new account;
- Write a review;
- Receive a coupon or giftcard once your review is accepted.
Click the button to start writing a review
Also for KCNK2 (NM_014217)
|A synthetic peptide within the N-terminal region [residues 1-100] of the human TREK 1 protein. [Swiss-Prot# Q9NRT2]|
|human, mouse, bovine
||WB: 2 ug/ml
|Tris-glycine, 150mM NaCl and 0.05% sodium azide|
|Immunogen affinity purified
|Homo sapiens potassium channel, two pore domain subfamily K, member 2 (KCNK2), transcript variant 2|
|hTREK-1c; hTREK-1e; K2p2.1; TPKC1; TREK; TREK-1; TREK1|
Entrez Gene 3776 Human
Entrez Gene 16526 Mouse
|A potential new target for antidepressants. Nature Neuroscience pp 1134-1141. A potassium channel called TREK1 may represent a new target for antidepressant drugs, according to research published in the September issue of Nature Neuroscience. The channel may exert its effects through a signaling pathway in the brain different to that normally targeted by most conventional antidepressants, which are thought to work by increasing the level of the neurotransmitter serotonin in the brain. Michel Lazdunski and colleagues studied mice lacking the gene for the TREK1 channel, which normally contributes to the background currents that set the resting membrane potential of neurons. In several behavioral tests used to model depression, these mice behaved as if they had been treated with an antidepressant. In addition, they had increased serotonergic activity, and did not release as much of the stress hormone corticosterone as normal mice in response to mild stress. Moreover, the authors report that the TREK1 channel was also directly inhibited by conventional antidepressants. The finding that mice lacking the gene for TREK1 behave as if they have been given an antidepressant suggests that small molecule 'blockers' of the potassium channel might be effective therapeutically. If TREK1 is found to exert its antidepressant effects through a pathway independent of serotonin, it is possible that future therapies targeting TREK1 channels may be faster acting and may have fewer side effects than conventional antidepressants. Deletion of the background potassium channel TREK-1 results in a depression-resistant phenotype pp. 1134-1141. Heurteaux C, Lucas G, Guy N, El Yacoubi M, Thummler S, Peng XD, Noble F, Blondeau N, Widmann C, Borsotto M, Gobbi G, Vaugeois JM, Debonnel G, Lazdunski M. Published online: 13 Aug 2006 | doi:10.1038/nn1749 TREK-1 is a two-pore-domain background potassium channel expressed throughout the central nervous system. It is opened by polyunsaturated fat|
|Ion Channels: PotassiumTransmembraneDruggable Genome |
* Availability is in business days
* OriGene provides validated application data and protocol, with money back guarantee.
Detection of TREK 1 in human brain membrane lysate